500 episódios
S19 Ep20: ESMO 2026 Data Continue to Shine a Spotlight on Daraxonrasib’s Activity in Pretreated Metastatic Pancreatic Cancer
13/11/2026 | 9minIn today's episode, we spoke with Zev A. Wainberg, MD, MSc, about subgroup data from the phase 3 RASolute 302 trial (NCT06625320) of daraxonrasib (Rasonque) in patients with previously treated metastatic pancreatic cancer, which were presented at the 2026 ESMO Congress. Dr Wainberg is a professor of medicine at the David Geffen School of Medicine at UCLA and co-director of the UCLA GI Oncology Program in Los Angeles, California.
In our exclusive interview, Dr Wainberg discussed how daraxonrasib improved overall survival (OS) vs investigator’s choice of standard-of-care chemotherapy across RAS genotype subgroups, preselected chemotherapy regimens, and prior treatment settings. Additionally, Dr Wainberg shared practical advice for managing rash and stomatitis, including treatment holds and dose reductions. Finally, Dr Wainberg explained how RAS(ON) inhibition is moving into earlier lines of therapy and why he supports genomic testing at diagnosis.
Dr Wainberg presented the analyses at the 2026 ESMO Congress on behalf of the RASolute 302 investigators. The trial randomly assigned 500 patients with metastatic pancreatic adenocarcinoma who had received 1 prior fluoropyrimidine- or gemcitabine-based regimen in the metastatic setting to daraxonrasib at 300 mg once daily (n = 248) or investigator’s choice of chemotherapy (n = 252). In the primary analysis, daraxonrasib generated a median OS of 13.2 months (95% CI, 10.0-not estimable) vs 6.7 months (95% CI, 5.8-8.0) with chemotherapy (HR, 0.40; 95% CI, 0.30-0.53; P = 4.6 × 10–11).
Dr Wainberg first addressed the subgroup findings by RAS genotype. RAS G12D and G12V mutations predominated, accounting for 43.2% and 35.6% of the study population, respectively, and Dr Wainberg noted that nearly every genotype subgroup favored daraxonrasib for OS. The OS HRs were 0.49 (95% CI, 0.33-0.74) in the G12D subgroup (n = 95 vs 121), 0.32 (95% CI, 0.19-0.54) in the G12V subgroup (n = 102 vs 76), 0.61 (95% CI, 0.29-1.30) in the G12R subgroup (n = 30 vs 31), and 0.43 (95% CI, 0.09-1.98) in patients with no RAS mutation identified (n = 9 vs 7).
Turning to sequencing, Dr Wainberg explained that neither the first-line regimen nor the chemotherapy selected for the control arm appeared to change the benefit of daraxonrasib. The OS HR was 0.45 (95% CI, 0.32-0.65) when gemcitabine plus nab-paclitaxel (Abraxane) was the preselected comparator (n = 140 vs 141), 0.46 (95% CI, 0.23-0.95) for pooled modified FOLFIRINOX or FOLFOX (n = 30 vs 30), and 0.32 (95% CI, 0.18-0.58) for nanoliposomal irinotecan (Onivyde) plus 5-fluorouracil and leucovorin (n = 78 vs 81).
Looking ahead, Dr Wainberg noted that trials of RAS(ON) inhibition are already enrolling in the adjuvant and first-line settings, and that many KRAS inhibitors presented at the meeting are moving quickly to phase 3 studies.S19 Ep19: RAS Inhibition With Daraxonrasib Marks a Turning Point in Pancreatic Cancer Management
13/11/2026 | 23minIn this episode of Oncology Unplugged, host Chandler Park, MD, MSc, FACP, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by John L. Marshall, MD, the chief of hematology and oncology, a professor of medicine and oncology, and the director of the Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center in Washington, DC.
Their discussion centered on the evolution of pancreatic adenocarcinoma management over the past several decades, culminating in the emergence of RAS-directed therapy. Drs Park and Marshall traced the treatment history from early regimens, such as fluorouracil/doxorubicin/mitomycin and single-agent fluorouracil, to the approval of gemcitabine based on clinical benefit, followed by years of gemcitabine-combination trials in which only capecitabine and nab-paclitaxel (Abraxane) produced positive results, and finally to FOLFIRINOX (leucovorin, fluorouracil, irinotecan, and oxaliplatin).
Dr Marshall explained RAS biology, emphasizing that since most pancreatic cancers harbor RAS mutations, severing this pathway can produce meaningful clinical benefit with a single agent, unlike in colorectal cancer. The experts reviewed data from the phase 3 RASolute 302 trial (NCT06625320) of the pan-RAS inhibitor daraxonrasib (Rasonque) presented at the 2026 ASCO Annual Meeting, in which second-line therapy yielded a median overall survival improvement vs chemotherapy. Dr Marshall tempered enthusiasm for these efficacy data by noting that response rates remained below 50% and that rash, affecting approximately 80% of patients, requires proactive prophylaxis, close follow-up, and dermatology collaboration. He cautioned against offering the agent to patients with poor performance status and discussed dose-optimization strategies.
Drs Park and Marshall also highlighted the importance of moving RAS inhibition into earlier lines of therapy, as only approximately 10% of patients are surgical candidates, as well as the need for comprehensive genomic testing, including germline BRCA1/2 testing to identify eligible candidates for treatment with olaparib (Lynparza). The conversation concluded with the potential role of artificial intelligence in predicting treatment benefit.- In today’s episode, we welcomed Noa Biran, MD, to discuss some of the key multiple myeloma data to emerge from the 2026 ASCO Annual Meeting. Dr Biran is the medical director of Clinical Protocol Data Management and an associate professor of medicine in the Multiple Myeloma Division at Hackensack Meridian Health and John Theurer Cancer Center in New Jersey.
In the exclusive interview, Dr Biran detailed key data from pivotal studies such as the phase 3 MajesTEC-9 (NCT05572515) and SUCCESSOR-2 (NCT05552976) trials, and explained how emerging data could affect the multiple myeloma treatment landscape. S19 Ep17: Perioperative Research Success Is Set to Transform Bladder Cancer Care After ESMO 2026
31/10/2026 | 56minIn this episode of Oncology Unplugged, host Chandler Park, MD, MSc, FACP, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Petros Grivas, MD, PhD, FASCO, the medical director of local/regional outreach and international program and a professor in the Clinical Research Division at Fred Hutch Cancer Center, as well as a professor in the Division of Hematology and Oncology at the University of Washington School of Medicine in Seattle.
Their discussion centered on key bladder cancer data presented at the 2026 ESMO Congress, highlighting the rapidly expanding landscape of perioperative, metastatic, and non–muscle-invasive disease management. Drs Park and Grivas first addressed findings from the phase 3 VOLGA trial (NCT04960709), which evaluated neoadjuvant durvalumab (Imfinzi) plus enfortumab vedotin-ejfv (Padcev), with or without tremelimumab (Imjudo), followed by cystectomy and adjuvant durvalumab in patients with cisplatin-ineligible or cisplatin-declining muscle-invasive bladder cancer. Dr Grivas noted that the durvalumab/enfortumab vedotin arm met both event-free survival (EFS) and overall survival (OS) end points, whereas the tremelimumab arm met the end point for EFS but not OS. He emphasized that the need for adjuvant enfortumab vedotin remains an open question.
The conversation then turned to the discordant results among trials in cisplatin-eligible patients. Dr Grivas contrasted the positive phase 3 NIAGARA trial (NCT03732677) data with the results of the phase 3 KEYNOTE-866 (NCT03924856) and ENERGIZE (NCT03661320) trials, which did not meet their EFS end points, and noted that all 3 enfortumab vedotin–based perioperative trials were positive. They also discussed exploratory circulating tumor DNA analyses from VOLGA and the phase 3 KEYNOTE-B15 study (NCT04700124), molecular subtype analysis findings from NIAGARA, and ongoing bladder-preservation trials.
Drs Park and Grivas also reviewed data in metastatic disease, including from cohort 7 of the phase 2 TROPHY-U-01 trial (NCT03547973), in which sacituzumab govitecan-hziy (Trodelvy) plus enfortumab vedotin and zimberelimab (AB122/GLS-010) yielded a high overall response rate. They also discussed data with sacituzumab tirumotecan (MK-2870/SKB264) plus pembrolizumab (Keytruda). In non–muscle-invasive disease, Dr Grivas discussed data from the phase 3 POTOMAC trial (NCT03528694) of durvalumab plus BCG and the role of shared decision-making in bladder cancer management. The experts concluded by highlighting developments in artificial intelligence, as well as the importance of patient advocacy and clinical trial participation.S19 Ep16: Thorough Treatment Adherence and Selection Anchor Proper TKI Utilization in CML
29/10/2026 | 9minIn our exclusive interview, Dr Haddad discussed the importance of consistent daily adherence to oral TKIs for achieving deep responses, treatment-free remission, and long-term survival in patients with CML. Additionally, he broke down common barriers to TKI adherence, including busy schedules, travel, and under-recognized adverse effects (AEs), underscoring the use of dose reductions and therapy changes to manage AEs and keep patients on treatment. Finally, Haddad explored where liquid and orally disintegrating TKI formulations, such as imatinib oral solution (Imkeldi), may help patients who cannot swallow, those with advanced-phase CML or Philadelphia chromosome–positive acute lymphoblastic leukemia, and pediatric patients.
Mais podcasts de Ciência
Podcasts em tendência em Ciência
Sobre OncLive® On Air
In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.
Site de podcastOuça OncLive® On Air, Hidden Brain e muitos outros podcasts de todo o mundo com o aplicativo o radio.net

Obtenha o aplicativo gratuito radio.net
- Guardar rádios e podcasts favoritos
- Transmissão via Wi-Fi ou Bluetooth
- Carplay & Android Audo compatìvel
- E ainda mais funções







































